STOCK TITAN
  1. Home
  2. News
  3. QDEL

QuidelOrtho Corporation - QDEL STOCK NEWS

Welcome to our dedicated page for QuidelOrtho Corporation news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on QuidelOrtho Corporation stock.

QuidelOrtho Corporation (symbol: QDEL) is a prominent American manufacturer specializing in diagnostic healthcare products that are distributed globally. The company focuses on the development, manufacturing, and marketing of rapid diagnostic testing solutions, which are crucial for both clinicians and patients worldwide. QuidelOrtho’s product portfolio includes immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing comprehensive solutions that aid in critical medical decisions.

With a strong geographical presence in North America, EMEA (Europe, the Middle East, and Africa), China, and other countries, QuidelOrtho generates the majority of its revenue from North America. The corporation is committed to innovation and quality, continually striving to improve diagnostic accuracy and efficiency.

Recent achievements of QuidelOrtho Corporation include significant advancements in rapid diagnostic testing technologies that ensure faster and more accurate results. The company has also entered strategic partnerships and launched new products that enhance its market position and expand its global footprint.

For investors and stakeholders, QuidelOrtho’s solid financial performance and ongoing projects demonstrate its robust growth potential. The company’s latest updates, news releases, and financial reports reflect its dedication to driving progress in the healthcare diagnostics industry.

Latest News:

  • SAN DIEGO--(BUSINESS WIRE)-- QuidelOrtho Corporation announces new strategic partnerships and product launches aiming to bolster its market presence.
News

QuidelOrtho Announces Changes in Executive Leadership

Rhea-AI Summary
QuidelOrtho Corporation (QDEL) terminates President and CEO, appoints interim leadership to drive operational efficiency and revenue growth. Board forms Office of the CEO to ensure business continuity. No change in financial guidance. Investor Day postponed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
none
-
News

QuidelOrtho Reports Fourth Quarter and Full-Year 2023 Financial Results

Rhea-AI Summary
QuidelOrtho Corporation (QDEL) reports strong momentum in Labs business with revenue of $743 million in Q4 2023. Non-respiratory revenue increased by 9%, while respiratory revenue decreased by 49%. Full-year 2023 revenue was $3.0 billion, with non-respiratory revenue up 61% and respiratory revenue down 61%. The company received regulatory clearances for new products and made significant debt repayments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.2%
Tags
earnings
-
News

QuidelOrtho to Report Fourth Quarter and Full-year 2023 Financial Results

Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) announced it will report its financial results for Q4 and full year 2023 on February 13, 2024. The company will hold a conference call to discuss the results, with access to the call provided on its website. Presentation materials will also be available on the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences earnings
News

QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
QuidelOrtho Corporation (NASDAQ:QDEL) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences
-
News

QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay

Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) has received 510(K) clearance from the U.S. Food and Drug Administration for its Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test, allowing them to market and sell the innovative platform to laboratories performing moderate or high complexity diagnostic testing in the United States. The platform delivers results in 25 minutes or less, improves clinical care, provides cost savings, and delivers sample-to-result molecular testing across all laboratory settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
News

QuidelOrtho to Participate in the Evercore ISI Conference

Rhea-AI Summary
QuidelOrtho Corporation (Nasdaq: QDEL) to Participate in Evercore ISI Conference on November 30, 2023. The company's President and CEO, Douglas Bryant, will join a fireside chat at 9:10 a.m. ET. The live webcast and replay will be accessible on the 'Events & Presentations' section of QuidelOrtho’s Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
News

QuidelOrtho Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
QuidelOrtho Corporation reported third-quarter revenue of $744 million, with strong respiratory demand and growth in non-respiratory businesses. Adjusted diluted earnings per share were $0.90, and adjusted EBITDA was $169 million with a margin of 23%. The company paid down $52 million of debt during the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
earnings
-
News

Powerful Lyme Disease Awareness PSA Featuring Christopher Meloni Illuminates Times Square

Rhea-AI Summary
Global Lyme Alliance produces chronic Lyme PSA with generous sponsorship from QuidelOrtho
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
News

QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023

Rhea-AI Summary
QuidelOrtho reports strong preliminary unaudited revenue results for Q3 2023, driven by higher respiratory product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
earnings
News

QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA

Rhea-AI Summary
QuidelOrtho receives CLIA Waiver for its Sofia 2 SARS Antigen+ FIA test, the first rapid antigen test for COVID-19 to receive this clearance. The test can now be used in CLIA-waived point-of-care settings, expanding its use. The Sofia 2 system provides an automated result in just 10 minutes, a 33% reduction in processing time. QuidelOrtho's commitment to innovation and accessibility is further demonstrated by this achievement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none

FAQ

What is the current stock price of QuidelOrtho Corporation (QDEL)?

The current stock price of QuidelOrtho Corporation (QDEL) is $37.89 as of November 21, 2024.

What is the market cap of QuidelOrtho Corporation (QDEL)?

The market cap of QuidelOrtho Corporation (QDEL) is approximately 2.6B.

What does QuidelOrtho Corporation specialize in?

QuidelOrtho Corporation specializes in the development, manufacturing, and marketing of rapid diagnostic testing solutions, including immunoassay and molecular testing, clinical chemistry, and transfusion medicine.

Where is QuidelOrtho Corporation headquartered?

QuidelOrtho Corporation is headquartered in the United States with a significant presence in North America, EMEA, China, and other countries.

What are the main products offered by QuidelOrtho?

QuidelOrtho offers a range of diagnostic healthcare products, including immunoassay and molecular testing solutions, clinical chemistry, and transfusion medicine products.

How does QuidelOrtho support clinicians and patients?

QuidelOrtho provides rapid diagnostic testing solutions that help clinicians and patients make informed and timely medical decisions, thereby improving healthcare outcomes.

What recent achievements has QuidelOrtho Corporation made?

QuidelOrtho has made significant advancements in rapid diagnostic testing technologies, strategic partnerships, and new product launches.

What regions contribute most to QuidelOrtho's revenue?

The majority of QuidelOrtho's revenue comes from North America, though the company also has a strong presence in EMEA, China, and other regions.

What is the stock symbol for QuidelOrtho Corporation?

The stock symbol for QuidelOrtho Corporation is QDEL.

How can I stay updated with the latest news about QuidelOrtho?

You can stay updated with the latest news about QuidelOrtho by following their official press releases and news updates on financial websites and stock market platforms.

Does QuidelOrtho engage in any partnerships?

Yes, QuidelOrtho engages in strategic partnerships to enhance its market presence and expand its product offerings globally.

What is the primary focus of QuidelOrtho's diagnostics?

QuidelOrtho primarily focuses on providing rapid, accurate, and reliable diagnostic testing solutions to support medical decision-making across the globe.

Stock QDEL logo
QuidelOrtho Corporation

Nasdaq:QDEL

QDEL Rankings

#1813 Ranked by Market Cap
N/A Ranked by Dividends

QDEL Stock Data

2.55B
58.02M
1.46%
108.55%
6.17%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
SAN DIEGO